2020
A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer.
Cecchini M, Miccio JA, Pahade J, Lacy J, Salem RR, Johnson SB, Blakaj A, Stein S, Kortmansky JS, Johung KL. A Single-Institution Experience of Induction 5-Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin Followed by Surgery Versus Consolidative Radiation for Borderline and Locally Advanced Unresectable Pancreatic Cancer. Pancreas 2020, 49: 904-911. PMID: 32658074, DOI: 10.1097/mpa.0000000000001592.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaLA PDACUnresectable pancreatic ductal adenocarcinomaInduction FOLFIRINOXConsolidative radiotherapyOverall survivalAdvanced unresectable pancreatic ductal adenocarcinomaSingle-center retrospective reviewMeaningful survival benefitMedian overall survivalUnresectable pancreatic cancerR0 resection rateKaplan-Meier methodSingle institution experienceBenefits of surgeryLog-rank testConsolidative radiationDefinitive radiationLA patientsPreoperative radiationResection rateSurgery patientsSurvival benefitSurvival impactImproved survival
2019
MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers.
Desai J, Kortmansky J, Segal N, Fakih M, Oh D, Kim K, Rahma O, Ko A, Chung H, Alsina M, Yeh K, Li S, Al-Sakaff N, Patel J, Barak H, Wang J, Zhang X, Bleul C, Cha E, Lee J. MORPHEUS: A phase Ib/II study platform evaluating the safety and clinical efficacy of cancer immunotherapy (CIT)–based combinations in gastrointestinal (GI) cancers. Journal Of Clinical Oncology 2019, 37: tps467-tps467. DOI: 10.1200/jco.2019.37.4_suppl.tps467.Peer-Reviewed Original ResearchPancreatic ductal adenocarcinomaII trialUnacceptable toxicityClinical benefitColorectal cancerSignificant survival benefitGastroesophageal junction cancerCancer immune responseImmune escape mechanismsMultiple tumor typesSingle control armPrimary endpointSecondary endpointsDurable responsesJunction cancerSurvival benefitTreatment armsClinical efficacyGastrointestinal cancerPT cohortCancer immunotherapyControl armDuctal adenocarcinomaImmune responseMinimal efficacy